Protocol No
MERCK-MK-7902-009
Phase
II
Summary
This project is being done to test the safety of the trial drugs, lenvatinib and pembrolizumab (pembro), for the treatment of head and neck squamous cell carcinoma (HNSCC) that has returned or spread after previous treatment.
Description
Lenvatinib with or without Pembrolizumab And SOC For R/M HNSCC After Platinum And Immunotherapy
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov